Drug Trial Radar · NCT04906460
Open-label Study of WVE-N531 in Patients With Duchenne Muscular Dystrophy (FORWARD-53)
Last checked: Nov 20, 2026Latest source record: Oct 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
25
Actual
Start
Sep 28, 2021
Primary completion
Oct 2026
Study completion Apr 24, 2027
Sponsor
- Lead sponsor
- Wave Life Sciences USA, Inc.Industry
- Sponsor type
- Industry
- First posted
- May 28, 2021
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Male only, from 4 years, up to 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase 1b/2 open-label study to evaluate the safety, tolerability, pharmacokinetic (PK), pharmacodynamic (PD), and clinical effects of intravenous (IV) WVE-N531 in patients with Duchenne muscular dystrophy (DMD). To participate in the study, patients must have a documented mutation of the DMD gene that is amenable to exon 53 skipping intervention. This study has 3 parts, Part A, Part B, including Part B Extension Arm, and Part C. Part A is completed. Part B is completed. Following completion of Part B, all patients elected to continue to receive study drug in the optional Part B open-label Extension Arm. Part C has been added to the study and will enroll new patients.
Conditions
- Duchenne Muscular Dystrophy
Interventions
WVE-N531Drug
WVE-N531 is an antisense oligonucleotide (ASO)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part A: Safety: Proportion of patients with adverse events (AEs)Time frame: Day 1 (initial dose) up to 24 weeks after the last dose of Part A
- Part B: Pharmacodynamics: Dystrophin level (% normal dystrophin) as assessed by Western blot of muscle tissue following multiple doses of WVE-N531Time frame: At Week 26 and at Week 50 of Part B
- Part C: Pharmacodynamics: Change from baseline dystrophin level (% normal dystrophin) as assessed by a validated assay analysis in muscle tissue following multiple doses of WVE-N531Time frame: At Baseline and following 24 weeks of treatment in Part C
Locations
6 sites in 3 countries. Site status is shown where the registry gives one.
Arkansas Children's Hospital
Little Rock, Arkansas
Rare Disease Research LLC
Atlanta, Georgia
Istiklal Hospital/ Clinical Research Unit
Amman, Jordan
The Specialty Hospital (TSH)/ Advanced Clinical Center
Amman, Jordan
King Abdullah University Hospital (KAUH)
Irbid, Jordan
Oxford Children's Hospital, Oxford University Hospitals NHS Foundation Trust
Headington, Oxford, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.